Health Economics and Outcomes Research (HEOR)
Building the evidence needed to demonstrate clinical value, quantify economic impact, and support better reimbursement and market access decisions.
HEOR is the discipline that translates clinical data into economic and outcomes evidence — the language that payers, HTA agencies, and health systems actually use to decide what gets reimbursed.
At Thelansis, we combine evidence generation, patient-centered outcomes research, health economic analysis, and value communication to address critical questions across the product lifecycle, from early development and evidence planning through HTA, reimbursement, and market access.
Budget Impact Model Precision
Real-World Evidence Integration
HTA Submission Alignment
Our work spans evidence synthesis and comparative effectiveness, disease burden analysis, patient-reported and quality-of-life outcomes, patient preference research, health economic modelling, cost-effectiveness and budget impact analyses, and HTA evidence development.
We support projects such as HEOR strategy and evidence gap assessments, systematic and targeted literature reviews, meta-analyses and NMAs, cost-effectiveness and budget impact models, early economic evaluations, value propositions, HTA evidence packages, and payer-focused evidence materials.
With experience across 20+ therapeutic areas and 30+ countries, Thelansis brings disease-area expertise, structured evidence workflows, and health-economic expertise to help clients identify evidence gaps early, quantify the value of their interventions, strengthen their value story, and make evidence-informed decisions on development, reimbursement, pricing, and access. Our approach pairs AI-enabled evidence acceleration with expert-led methodological review, reducing manual effort and turnaround time without compromising the rigor and transparency payer and HTA decisions require.
Our Pillars
Delivering robust evidence, economic models, and strategic market access solutions for successful healthcare decision-making.
Evidence Generation & Patient-Centered Outcomes
We build a robust evidence base for disease burden, treatment outcomes, comparative effectiveness, and patient priorities through literature reviews, meta-analyses, NMAs, real-world evidence, QoL, PROs, and patient preference research, ensuring value assessments reflect what matters to patients, caregivers, clinicians, and payers. AI speeds screening and extraction; HEOR experts validate every output.
Economic Modelling & Health Economics
We quantify diseases and treatments clinical and economic impact through robust, decision-relevant models: cost-effectiveness, cost-utility, budget-impact, and burden-of-illness, built via Markov, decision-tree, partitioned-survival, patient-level, and hybrid approaches suited to disease and evidence. AI aids input identification and workflows; health economists validate every model for rigor and relevance.
HTA Evidence & Value Communication
We turn clinical, economic, and patient-centered evidence into compelling value narratives and decision-ready packages for HTA and market access, spanning HTA assessments, evidence gap analysis, global value dossiers, value propositions, payer materials, and stakeholder communication. HEOR experts and scientific writers ensure accurate, HTA-aligned communication across markets and the product lifecycle.
Powered By One Enabling Layer
AI-Enabled Evidence Acceleration: AI-enabled workflows that help clients generate high-quality evidence faster, more efficiently, and at lower operational cost, without compromising scientific rigor.
We embed AI across our HEOR workflows to reduce manual effort, accelerate evidence generation, and improve research efficiency across literature review, evidence synthesis, data extraction, evidence structuring, and modelling support. AI-assisted workflows can accelerate literature screening, study identification, structured data extraction, evidence mapping, qualitative synthesis, input identification, model conceptualization, and consistency checks, reducing turnaround times and the operational effort associated with repetitive evidence-generation activities.
For clients, this translates into faster evidence cycles, reduced manual workload, greater scalability, and potential cost efficiencies, enabling teams to evaluate more evidence and generate decision-ready outputs within shorter timelines. Technology accelerates the workflow; our HEOR experts remain accountable for methodological decisions, evidence interpretation, quality control, model validation, and final deliverables- the combination that lets us deliver faster without sacrificing the scientific credibility that high-stakes healthcare decisions require.
What We Do
Thelansis delivers end-to-end HEOR and evidence strategies to support your drug’s clinical and economic value. Our capabilities include:
Key Deliverables
Our HEOR deliverables translate clinical and economic value into practical tools that drive market access and informed decision-making. Typical outputs include:
Evidence gap analysis & evidence generation roadmap
SLR/meta-analysis reports and NMA outputs
Cost-effectiveness, cost-utility, and budget impact models
Burden-of-illness / cost-of-illness reports
RWE study protocols and analysis reports
Global value dossiers (AMCP/EU-style formats)
HTA submission packages (country-adapted)
Payer value communication toolkits
QoL/PRO evidence syntheses and instrument recommendations
Pricing and access scenario models
Benefits of Partnering with Thelansis
Partnering with Thelansis ensures your biopharma assets are backed by evidence and economic rigor, accelerating market access and payer adoption. Our clients benefit from:
Deep expertise across 20+ therapeutic areas
Our HEOR built on real datasets, expertise across 20+ therapeutic areas — not a template
One team across evidence and disease burden
No handoff friction — epi and HEOR are one team, from disease model to value dossier
Positioned for where HEOR is heading
AI-assisted acceleration with senior oversight — built forward, not retrofitted later
Global market fluency
Cost-efficient delivery from India, with client-facing presence across the US and EU
Ready to build an evidence strategy that survives payer scrutiny?
Accelerate your product launch with evidence strategies that turn complex clinical data into clear economic value for payers and HTA agencies.